Evidence mapPaperPMID 42226239Full record

ArticleBMC cancer2026

Breast cancer survival prediction using machine learning and multimodal data for personalized care plan.

Nasibeh Rady Raz, Nahid Nafissi, Ebrahim Babaee, Pedram Fadavi

Abstract read
In one paragraph

Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nasibeh Rady RazBreast Cancer Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran. radyraz.n@iums.ac.ir.ORCID http://orcid.org/0000-0003-1039-1589
Nahid NafissiBreast Cancer Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran. nafissi.n@iums.ac.ir.ORCID http://orcid.org/0000-0001-7454-9985
Ebrahim BabaeePreventive Medicine and Public Health Research Center, Psychosocial Health Research Institute, Community and Family Medicine Department, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0001-7969-9122
Pedram FadaviBreast Cancer Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran.ORCID http://orcid.org/0000-0001-7491-2561

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This paper presents a time-stratified breast cancer survival analysis that incorporates tumor characteristics, disease stage, and patient features, using machine learning (ML) algorithms to support personalized care planning. Considering nonlinear relationships between input data and the risk of death, as well as the dynamics of patient characteristics over time, we utilize 6 ML algorithms, including XGBoost, Logistic Regression, Random Forest, Decision Tree, AdaBoost, and Multilayer Perceptron, for less than 6 months, 6 months, 1-, 2-, 3-, 5-, and 10-year survival rates prediction. We utilize multimodal data from 3,476 breast cancer patients, comprising 43 features. XGBoost outperforms the rest, achieving an accuracy of over 90%. The top five predictors, using Shapley Additive exPlanations (SHAP), include DCIS, Ki-67, age, feeding, and lymph node grade. SHAP analysis indicated that lower values of DCIS and Ki-67, lower lymph node and tumor grade, less sentinel lymph node involvement, higher age, longer duration of breastfeeding, lower tumor size, medullary tumor type, PR+, ER+, less positive node, more pregnancy, DCIS pathology class, BCS surgery type for early-stage, lower tumor stage, no necrosis, HER2-, no family history, and no calcification are result in longer breast cancer survival. Furthermore, we validate the model's performance using 5-fold cross-validation (CV) and nested CV. We also evaluate model performance using accuracy, precision, F1 score, and recall. All results show the proposed method outperforms. This paper presents clinical, molecular, and demographic insights into survival analysis, utilizing explainable ML techniques to support personalized treatment decisions.

Indexed as

Breast NeoplasmsMachine LearningPrecision MedicineAdultAgedBoosting Machine Learning AlgorithmsClassification AlgorithmsFemaleHumansMiddle AgedPrediction AlgorithmsPredictive Learning ModelsPrognosisRandom ForestSurvival AnalysisArtificial IntelligenceBreast CancerMachine LearningPersonalized TreatmentSurvival Analysis

Identifiers

PMID42226239
PMCPMC13455422

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.